Navigation Links
New Stool Test Might Aid in Early Detection of Colon Cancer
Date:4/3/2012

TUESDAY, April 3 (HealthDay News) -- A noninvasive stool test could help doctors detect early stage colorectal cancer and precancerous growths, a new study says.

The test might help minimize false-positive results and prevent deaths associated with this type of cancer, said researchers at the Mayo Clinic in Rochester, Minn., and Exact Sciences, the company developing the test.

Still, other issues remain, and experts say that the stool-based test won't replace colonoscopy anytime soon as the best means of spotting colon polyps or tumors.

"For now, colonoscopy remains the undisputed winner when it comes to screening for colon cancer," said Dr. Lawrence Cohen, associate clinical professor of gastroenterology at Mount Sinai School of Medicine in New York City. He was not involved in the study.

The research was to be presented Tuesday at the annual meeting of the American Association for Cancer Research (AACR) in Chicago.

The new stool-based screen targets multiple molecular "markers" in stool. Tested in 500 patients who were also undergoing colonoscopy or follow-up care after the detection of colon polyps, researchers found that the screen was highly sensitive to certain critical early cancer screening targets. Unlike other stool-based colon cancer tests, the new test also seemed to be unaffected by patients' medications, sex, race, body mass, lifestyle or family history of colorectal cancer or polyps.

These results mean that "patients don't have to change their lifestyle to have this test," Dr. David Ahlquist, professor of medicine and a consultant in gastroenterology and hepatology at the Mayo Clinic, said in an AACR meeting news release. "That was important from a patient-friendly standpoint for a test like this and could benefit compliance."

The study's authors noted, however, that a patient's age was the one variable that seemed to influence test results. Based on the study's findings, the two markers least vulnerable to age would undergo further test development.

"This test, if broadly applied, should have a very important impact on reducing both the mortality and incidence of colorectal cancer," Ahlquist said. "If we can minimize the false positives, that will reduce the cost of the whole screening program by avoiding unnecessary colonoscopies."

The screening test is currently undergoing FDA validation in a study in the United States and Canada. This study is expected to conclude in the fall.

The Mayo Clinic and Ahlquist reported having a financial interest in the screening technology.

Experts in colon cancer prevention said the test seems to have pros and cons.

"This test offers significant potential to improve upon current stool-based tests as it is unaffected by diet, lifestyle and other important factors which affect current stool-based testing," noted Dr. David Bernstein, chief of the division of gastroenterology at North Shore University Hospital in Manhasset, N.Y.

"The need for colonoscopy, however, would be unlikely to change as this test relies upon specific colon cancer gene markers which may not account for all cases of colon cancer," he added. "This test may be useful in distinguishing low- from high-risk individuals at risk for colon cancer."

For his part, Cohen said the particular gene-based approach used by the Mayo screen is "likely to improve the sensitivity and specificity of this stool DNA test." But he said that stool-based screening still falls short in accurately spotting certain precancerous lesions of the colon compared to colonoscopy.

"An additional challenge for stool testing is cost," Cohen added. "Cost analyses of stool DNA testing have found it to be less cost-effective than any other method of colorectal screening," he said.

Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute provides more information on colon and rectal cancer.

-- Mary Elizabeth Dallas

SOURCE: David Bernstein, M.D., chief, division of gastroenterology, North Shore University Hospital, Manhasset, N.Y.; Lawrence B. Cohen, M.D., associate clinical professor, gastroenterology, Mount Sinai School of Medicine, New York City; American Association for Cancer Research, news release, April 3, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Stool DNA testing could play expanded role in colon cancer prevention
2. New Scanning Technology Might Help Guide Prostate Cancer Care
3. Diabetes Drug Metformin Might Also Help Fight Cancer
4. Moderate Drinking Might Help Men Live Longer After Heart Attack
5. New Injection Might Lower Tough-to-Treat Cholesterol
6. Study Explains How Shock Therapy Might Ease Severe Depression
7. Poor Reading Skills Might Be Fatal for Older Folks
8. CYFRA21-1 might be predictive marker in advanced NSCLC
9. Detailed Gene Scan Might Help Guide Leukemia Treatment
10. Inflammation Might Play Role in Heart Disease: Study
11. Fatty Foods Might Harm Mens Sperm, Research Suggests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Stool Test Might Aid in Early Detection of Colon Cancer
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology: